Dapagliflozin for anemia in kidney disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with chronic kidney disease stage 3 or 4 (moderate to severe kidney damage).
- You have anemia caused by your kidney disease, and your hemoglobin level is below 11.5 g/dL.
- You are already receiving medication (like epoetin or darbepoetin) to treat your anemia.
- Your anemia is not due to other causes like pernicious anemia, thalassemia, sickle cell disease, or bone marrow problems.
- You have not had a heart attack, stroke, or severe heart failure in the last 6 months, and you do not have active cancer or a recent cancer history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This trial tests whether a diabetes medicine called dapagliflozin can help improve anemia (low red blood cell count) in people with lower-risk myelodysplastic syndromes. Myelodysplastic syndromes are a group of blood disorders where the bone marrow doesn't make enough healthy blood cells. The study aims to see if this drug can help you feel better by boosting your blood counts.
This study tests a medication called dapagliflozin to see if it can reduce inflammation and improve red blood cell and iron levels in people with type 2 diabetes and chronic kidney disease.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
Hear when a new Chronic Kidney Disease(CKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.